Advanced search
Publication Cover
ClinicoEconomics and Outcomes Research Volume 8, 2016 - Issue
Submit an article Journal homepage
386
Views
14
CrossRef citations to date
0
Altmetric
Original Research

Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US

Jeffrey D Miller1 Truven Health Analytics Inc, Cambridge, MA, USACorrespondence[email protected]
,
Xin Ye2 Daiichi Sankyo Inc, Parsippany, NJ, USA
,
Gregory M Lenhart1 Truven Health Analytics Inc, Cambridge, MA, USA
,
Amanda M Farr1 Truven Health Analytics Inc, Cambridge, MA, USA
,
Oth V Tran1 Truven Health Analytics Inc, Cambridge, MA, USA
,
W Jackie Kwong2 Daiichi Sankyo Inc, Parsippany, NJ, USA
,
Elizabeth A Magnuson3 St Luke Mid-America Heart Institute, Kansas City, MO, USA
&
William S Weintraub4 Center for Heart and Vascular Health, Christiana Care Health System, Newark, DE, USA
 show all
Pages 215-226 | Published online: 20 May 2016

Citations (14)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

J. Maervoet, N. Bossers, R. P. Borge$suffix/text()$suffix/text(), S. Thompson Hilpert, A. van Engen & A. Smala. (2019) Use of insertable cardiac monitors for the detection of atrial fibrillation in patients with cryptogenic stroke in the United States is cost-effective. Journal of Medical Economics 22:11, pages 1221-1234.
Read now
Carlos Escobar Cervantes, José Luis Merino & Vivencio Barrios. (2019) Edoxaban for the prevention of stroke in patients with atrial fibrillation. Expert Review of Cardiovascular Therapy 17:4, pages 319-330.
Read now
Philip S. Wells, Anthonie W. A. Lensing, Lloyd Haskell, Bennett Levitan, François Laliberté, Michael Durkin, Veronica Ashton, Yongling Xiao, Concetta Crivera, Dominique Lejeune, Jeff Schein & Patrick Lefebvre. (2018) Cost comparison of continued anticoagulation with rivaroxaban versus placebo based on the 1-year EINSTEIN-Extension trial efficacy and safety results. Journal of Medical Economics 21:6, pages 587-594.
Read now
Peter Bo Poulsen, Søren Paaske Johnsen, Morten Lock Hansen, Axel Brandes, Steen Husted, Louise Harboe & Lars Dybro. (2017) Setting priorities in the health care sector – the case of oral anticoagulants in nonvalvular atrial fibrillation in Denmark. ClinicoEconomics and Outcomes Research 9, pages 617-627.
Read now

Articles from other publishers (10)

Mitchell S. V. Elkind, Klaus K. Witte, Scott E. Kasner, Laura M. Sawyer, Frank W. Grimsey Jones, Claudia Rinciog, Stelios Tsintzos, Sarah C. Rosemas, David Lanctin, Paul D. Ziegler & Matthew R. Reynolds. (2023) Cost-effectiveness of an insertable cardiac monitor in a high-risk population in the US. BMC Cardiovascular Disorders 23:1.
Crossref
Rini Noviyani, Sitaporn Youngkong, Surakit Nathisuwan, Bhavani Shankara Bagepally, Usa Chaikledkaew, Nathorn Chaiyakunapruk, Gareth McKay, Piyamitr Sritara, John Attia & Ammarin Thakkinstian. (2022) Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: a systematic review and meta-analysis. BMJ Evidence-Based Medicine 27:4, pages 215-223.
Crossref
Rachel S. Dada, J.W. Awori Hayanga, Kaitlin Woods, David Schwartzman, Dylan Thibault, Matthew Ellison, Stanley Schmidt, Donald Siddoway, Vinay Badhwar & Heather K. Hayanga. (2021) Anesthetic Choice for Atrial Fibrillation Ablation: A National Anesthesia Clinical Outcomes Registry Analysis. Journal of Cardiothoracic and Vascular Anesthesia 35:9, pages 2600-2606.
Crossref
Katherine VilainHaiyan LiWingham J. KwongElliott M. AntmanChristian T. RuffEugene Braunwald, David J. Cohen, Robert P. GiuglianoElizabeth A. Magnuson. (2020) Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF–TIMI 48 Trial. Circulation: Cardiovascular Quality and Outcomes 13:11.
Crossref
Jörg Tomeczkowski, Sven Dillenburger & Joerg Mahlich. 2020. Digitale Transformation von Dienstleistungen im Gesundheitswesen VII. Digitale Transformation von Dienstleistungen im Gesundheitswesen VII 209 240 .
Jonathan Salcedo, Joel W. Hay & Jenny Lam. (2019) Cost-effectiveness of rivaroxaban versus warfarin for treatment of nonvalvular atrial fibrillation in patients with worsening renal function. International Journal of Cardiology 282, pages 53-58.
Crossref
Thananan Rattanachotphanit, Chulaporn Limwattananon, Onanong Waleekhachonloet, Phumtham Limwattananon & Kittisak Sawanyawisuth. (2018) Cost-Effectiveness Analysis of Direct-Acting Oral Anticoagulants for Stroke Prevention in Thai Patients with Non-Valvular Atrial Fibrillation and a High Risk of Bleeding. PharmacoEconomics 37:2, pages 279-289.
Crossref
Alexa R. Hospodar, Kenneth J. Smith, Yuting Zhang & Inmaculada Hernandez. (2018) Comparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding. American Journal of Cardiovascular Drugs 18:4, pages 317-325.
Crossref
Inmaculada Hernandez, Kenneth J. Smith & Yuting Zhang. (2017) Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function. Thrombosis Research 150, pages 123-130.
Crossref
. (2016) Edoxaban dominates rivaroxaban for stroke prevention in NVAF. PharmacoEconomics & Outcomes News 754:1, pages 13-13.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.